ILUMYA® (tildrakizumab-asmn) is approved in the US for the treatment of adults with active psoriatic arthritis.
🇺🇸 USA · Map
ILUMYA® (tildrakizumab-asmn) is approved in the US for the treatment of adults with active psoriatic arthritis.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in